Shares in Ocular Therapeutix (NSDQ:OCUL) rose more than 5% today after the company said its Dextenza post-surgical ocular pain relief implant met primary endpoints in the company’s most recent Phase III trial. The hydrogel plug, inserted into a patient’s tear duct, is designed to deliver a sustained dose of dexamethasone over 4 weeks following ophthalmic surgery. […]
Optical/Ophthalmic
Regeneron posts mixed Q1 results, Eylea growth slows
Shares in Regeneron (NSDQ:REGN) rose today after the company beat revenue expectations on The Street with its 1st quarter financial results. The company’s total sales rose to $1.32 billion, exceeding analysts’ estimate of $1.30 billion. Regeneron’s bottom line jumped 37% to $248.9 million. Adjusted to exclude 1-time items, earnings per share were $2.92, which missed analysts’ […]
Glaukos shares tumble despite Q1 beat
Shares in Glaukos (NYSE:GKOS) fell -10% today after the ophthalmic medtech company beat expectations on Wall Street with its 1st quarter results. The San Clemente, Calif.-based company posted profits of $878,000, or 2¢ per share, on sales of $35.9 million for the 3 months ended March 31, for bottom-line loss of -2% on sales growth of […]
Kala touts Phase III data for nanoparticle ophthalmic suspension
Kala Pharmaceuticals touted data today from a Phase III trial of its nanoparticle formulation of loteprednol etabonate as a treatment for inflammation and pain in cataract surgery patients. The KPI-121 1% suspension met both primary efficacy endpoints and secondary endpoints and was well tolerated by the trial’s participants. The Waltham, Mass.-based company’s KPI-121 uses Kala’s mucus-penetrating […]
Novartis misses on rev, tops sales estimates in Q1
Shares in Novartis (NYSE:NVS) rose today after the pharmaceutical company met expectations on Wall Street with its 1st quarter earnings, but missed on sales largely thanks to growing pressure from generics to the company’s top-selling chemotherapy, Gleevec. The company posted profits of $1.92 billion, or 22¢ per share, on sales of $11.53 billion for the 3 months […]
How IBM is using deep learning to detect diabetic eye disease
IBM’s deep learning technology can detect and classify the severity of diabetic retinopathy with 86% accuracy, according to new research. The diagnostic tool could help doctors and physicians better understand disease progression and determine treatment, IBM said. The company’s technology was trained to identify lesions using more than 35,000 eye images. It can classify the […]
Eyevensys wins approval to start clinical development of EyeCET platform
Private biotech Eyevensys said today that it won approval from the UK Medicines and Healthcare Products Regulatory Agency to advance its EyeCET platform into clinical development. The company’s EyeCET platform uses an electro-transfection injection system to deliver non-viral plasmids that encode for disease-specific therapeutic proteins in the ciliary muscle of the eye. Eyevensys’ lead product […]
Clearside closes patient enrollment in trial for diabetic macular edema therapy
Clearside Biomedical (NSDQ:CLSD) said today that it finished enrollment for the Phase 1/2 study of CLS-TA in patients with diabetic macular edema. The Hulk trial is designed to evaluate the safety and efficacy of a suprachoroidal injection of its suspension formulation of a corticosteroid, triamcinolone acetonide, with and without an intravitreal injection of Eylea in […]
Imprimis, Precision Lens sign marketing and sales agreement
Imprimis Pharmaceuticals (NSDQ:IMMY) said today that it signed a 3-year exclusive sales agreement with Precision Lens. According to the deal, Precision Lens plans to deploy a sales team to expand Imprimis’ ophthalmic portfolio in 13 states across the U.S. Midwest. Precision Lens said it will sell San Diego-based Imprimis’ Dropless Therapy, LessDrops combination eye drops […]
Medtech stories we missed this week: April 14, 2017
From FDA approvals to business expansion plans, here are medtech stories we missed this week but thought were still worth mentioning. 1. BioTelemetry launches offer to acquire LifeWatch BioTelemetry and LifeWatch announced in an April 9 press release that the 2 companies have entered a transaction agreement that states BioTelemetry will launch a tender offer to acquire all […]